Navigation Links
Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP
Date:11/12/2009

LAKE FOREST, Ill., Nov. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"Bioniche Pharma is very pleased to expand our product line with these injectable drugs," said Steve Thornton, Bioniche Pharma CEO. "These two products represent our commitment to expanding our product line with a combination of brand and generic drugs, which strengthens our position as a specialty injectables pharmaceutical company."

Duraclon®(clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management. Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction. Please refer to the Bioniche Pharma website for the complete prescribing information, including the boxed warnings, for these products.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com .

Duraclon® is a registered trademark of Astellas US LLC

SOURCE Bioniche Pharma


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
2. Bioniche Reports Fiscal 2009 Year-End Results
3. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
4. Bioniche Repays Revolving Credit Facility
5. Bioniche Provides a Corporate Update
6. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
7. Bioniche Represented at House of Commons Sub-Committee on Food Safety
8. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
9. Bioniche Reports Fiscal 2009 Third Quarter
10. Bioniche Provides a Corporate Update
11. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... on patients with cancer, has added Cancer and Careers to its ... more timely content on continuing successful careers while fighting cancer. , As partners, ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... inside of FCPX," said Christina Austin - CEO of Pixel Film Studios. ... within Final Cut Pro X. Choose from abstract transitions to more simple wipes ...
(Date:5/30/2016)... Texas (PRWEB) , ... May 30, 2016 , ... Another ... 7 am in Plano, located at 3960 Legacy Drive, Plano, TX and is open ... Plano Chamber of Commerce followed by a medical open house. The Jasper High School ...
(Date:5/29/2016)... Viejo, CA (PRWEB) , ... May 29, 2016 , ... ... Volume 3 let's the user control the style of their project," said Christina Austin ... set of 30 self-animating web-themed intros created exclusively for use in Final Cut Pro ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... -- , Isansys  Lifecare, a new generation digital ... wireless patient monitoring platform, as it ships more systems to ... , Scotland and Norway ... system, launched earlier this year, is now being used in ... This new technology significantly enhances the user experience and ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... , May 30, 2016 Eye expert ... of premature babies to seek an eye examination ... condition     Moorfields Eye Hospital Dubai, ... London , has identified premature babies as a ... because of their particular vulnerability to retinopathy of prematurity (ROP). ROP ...
Breaking Medicine Technology: